Previous 10 | Next 10 |
Gainers: Ra Medical Systems (RMED) +67%, Nemaura Medical (NMRD) +23%, Lucira Health (LHDX) +21%, Minerva Neurosciences (NERV) +20%, Harrow Health (HROW) +19%.Losers: InflaRx (IFRX) -15%, Praxis Precision Medicines (PRAX) -14%, Lianlu...
Minerva Neurosciences (NERV) is up more than 27% in morning trading after the company announced positive results from an open-label extension of a phase 3 trial of its schizophrenia candidate roluperidone.The drug demonstrated continuous improvement in negative symptoms, continuous ...
Thinking about buying stock in Minerva Neurosciences, Fubotv, Lucira Health, Biomerica, or Comstock Mining? PR Newswire NEW YORK , May 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NERV, FUBO, LHDX, BMRA, and LODE. ...
Second Sight Medical Products (EYES) +24% on reporting two-year results of its Orion study.Upstart Holdings (UPST) +23% on Q1 results.Minerva Neurosciences (NERV) +23% on Q1 results.fuboTV Inc. (FUBO) +21% on Q1 results.Biomerica (BMRA) +17%.Lucira Health (LHDX) +16% ...
Minerva Neurosciences (NERV): Q1 GAAP EPS of -$0.21 misses by $0.54.Cash, cash equivalents, and restricted cash at March 31, 2021 were approximately $80.2 million.Press Release For further details see: Minerva Neurosciences EPS misses by $0.54
Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms, improved functional ability, favorable safety profile and limited number of psychotic relap...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors, and get ready for another busy day of trading! We’re back at it again with a look at the biggest pre-market stock movers for Wednesday. Expect a lot of earnings news to be affecting stock as ...
Minerva Neurosciences (NERV) shares surge over 35% during post-market trading after the company posted promising results from its open-label extension ((OLE)) of the late-stage trial of roluperidone for the treatment of negative symptoms ((NS)) of schizophrenia.In the double-bl...
Key results Continuous improvement in negative symptoms as measured by Positive and Negative Syndrome Scale (PANSS) Marder Negative Symptom Factor Score (NSFS) observed over one year (12-week double-blind and 40-week open-label periods) in patients receiving both 64 mg a...
WALTHAM, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and busines...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...